BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)

January 15, 2026 8:25 AM EST Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $258.00 price target on Abbvie (NYSE: ABBV).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login